In Europe, the Middle East and Africa, Astellas has an expansive business  platform, selling products in around 70 countries through more than 20 sales  subsidiaries and external distributors. Our strategic priorities are to expand the urology franchise, sustain the  transplantation business, and quickly establish a business platform in the  oncology field. In fiscal 2013, we continued to achieve growth in the OAB fran- chise combining Vesicare and BETMIGA as we worked to develop a sales  organization in preparation for the launch of XTANDI. The business environment is being reshaped by various trends including the  increasing importance of economic assessments in determining drug reim- bursement prices, as well as more stringent polices to curb medical expendi- tures in line with fiscal austerity measures. Meanwhile, emerging markets  continue to expand. We will respond flexibly to these changes in the environment and ensure  that we seize on opportunities to expand business with the aim of driving  sustained growth. Ken Jones President and CEO, EMEA Operations Sales of Mainstay Products ( €  million) ( €  million) 2013.3 J-GAAP 2014.3 2015.3 (Forecast) IFRS J-GAAP IFRS Sales in EMEA 1,834 $_{⬆}$ 1,990 1,967 $_{⬆}$ 2,183 Treatment for the functional symptoms  associated with benign prostatic  hyperplasia Omnic, Omnic OCAS (Harnal) 181 ⬇ 177 176 ⬇ 162 Sales by Astellas 144 $_{⬆}$ 145 144 ⬇ 133 Bulk and Royalties 37 ⬇ 32 32 ⬇ 29 Immunosuppressant Prograf and Advagraf (Incl. exports to third parties) 577 ⬇ 568 565 ⬇ 536 Sales by Astellas 537 ⬇ 530 527 ⬇ 510 Exports to third parties 40 ⬇ 38 38 ⬇ 26 OAB treatment Vesicare 281 $_{⬆}$ 317 303 $_{⬆}$ 307 OAB treatment BETMIGA (Launched in February 2013) 0 $_{⬆}$ 15 15 $_{⬆}$ 66 Treatment for atopic dermatitis Protopic 43 $_{⬆}$ 53 52 $_{⬆}$ 53 Candin-type antifungal agent MYCAMINE 56 $_{⬆}$ 65 64 $_{⬆}$ 72 Advanced prostate cancer treatment Eligard 140 ⬇ 139 136 $_{⬆}$ 149 Prostate cancer treatment XTANDI (Launched in July 2013) — $_{⬆}$ 71 70 $_{⬆}$ 190 Peripheral neuropathic pain treatment Qutenza 8 $_{⬆}$ 11 11 Anti-infective agent DIFICLIR 10 9 Sales of Major Products Annual Report 2014 _  Astellas Pharma Inc.  49  Vesicare   BETMIGA  Eligard   XTANDI 400 300 200 100 0 2012.3 2013.3 2014.3 2015.3 J-GAAP IFRS (Forecast) Review of Operations